449 related articles for article (PubMed ID: 25625931)
1. The evolution of the EGFRvIII (rindopepimut) immunotherapy for glioblastoma multiforme patients.
Paff M; Alexandru-Abrams D; Hsu FP; Bota DA
Hum Vaccin Immunother; 2014; 10(11):3322-31. PubMed ID: 25625931
[TBL] [Abstract][Full Text] [Related]
2. Greater chemotherapy-induced lymphopenia enhances tumor-specific immune responses that eliminate EGFRvIII-expressing tumor cells in patients with glioblastoma.
Sampson JH; Aldape KD; Archer GE; Coan A; Desjardins A; Friedman AH; Friedman HS; Gilbert MR; Herndon JE; McLendon RE; Mitchell DA; Reardon DA; Sawaya R; Schmittling R; Shi W; Vredenburgh JJ; Bigner DD; Heimberger AB
Neuro Oncol; 2011 Mar; 13(3):324-33. PubMed ID: 21149254
[TBL] [Abstract][Full Text] [Related]
3. Rindopepimut: a promising immunotherapeutic for the treatment of glioblastoma multiforme.
Swartz AM; Li QJ; Sampson JH
Immunotherapy; 2014; 6(6):679-90. PubMed ID: 25186601
[TBL] [Abstract][Full Text] [Related]
4. Phase I/IIa trial of fractionated radiotherapy, temozolomide, and autologous formalin-fixed tumor vaccine for newly diagnosed glioblastoma.
Ishikawa E; Muragaki Y; Yamamoto T; Maruyama T; Tsuboi K; Ikuta S; Hashimoto K; Uemae Y; Ishihara T; Matsuda M; Matsutani M; Karasawa K; Nakazato Y; Abe T; Ohno T; Matsumura A
J Neurosurg; 2014 Sep; 121(3):543-53. PubMed ID: 24995786
[TBL] [Abstract][Full Text] [Related]
5. Immunologic escape after prolonged progression-free survival with epidermal growth factor receptor variant III peptide vaccination in patients with newly diagnosed glioblastoma.
Sampson JH; Heimberger AB; Archer GE; Aldape KD; Friedman AH; Friedman HS; Gilbert MR; Herndon JE; McLendon RE; Mitchell DA; Reardon DA; Sawaya R; Schmittling RJ; Shi W; Vredenburgh JJ; Bigner DD
J Clin Oncol; 2010 Nov; 28(31):4722-9. PubMed ID: 20921459
[TBL] [Abstract][Full Text] [Related]
6. A phase II, multicenter trial of rindopepimut (CDX-110) in newly diagnosed glioblastoma: the ACT III study.
Schuster J; Lai RK; Recht LD; Reardon DA; Paleologos NA; Groves MD; Mrugala MM; Jensen R; Baehring JM; Sloan A; Archer GE; Bigner DD; Cruickshank S; Green JA; Keler T; Davis TA; Heimberger AB; Sampson JH
Neuro Oncol; 2015 Jun; 17(6):854-61. PubMed ID: 25586468
[TBL] [Abstract][Full Text] [Related]
7. Targeting EGF receptor variant III: tumor-specific peptide vaccination for malignant gliomas.
Del Vecchio CA; Li G; Wong AJ
Expert Rev Vaccines; 2012 Feb; 11(2):133-44. PubMed ID: 22309662
[TBL] [Abstract][Full Text] [Related]
8. Rindopepimut with temozolomide for patients with newly diagnosed, EGFRvIII-expressing glioblastoma (ACT IV): a randomised, double-blind, international phase 3 trial.
Weller M; Butowski N; Tran DD; Recht LD; Lim M; Hirte H; Ashby L; Mechtler L; Goldlust SA; Iwamoto F; Drappatz J; O'Rourke DM; Wong M; Hamilton MG; Finocchiaro G; Perry J; Wick W; Green J; He Y; Turner CD; Yellin MJ; Keler T; Davis TA; Stupp R; Sampson JH;
Lancet Oncol; 2017 Oct; 18(10):1373-1385. PubMed ID: 28844499
[TBL] [Abstract][Full Text] [Related]
9. Long-term Survival in Glioblastoma with Cytomegalovirus pp65-Targeted Vaccination.
Batich KA; Reap EA; Archer GE; Sanchez-Perez L; Nair SK; Schmittling RJ; Norberg P; Xie W; Herndon JE; Healy P; McLendon RE; Friedman AH; Friedman HS; Bigner D; Vlahovic G; Mitchell DA; Sampson JH
Clin Cancer Res; 2017 Apr; 23(8):1898-1909. PubMed ID: 28411277
[No Abstract] [Full Text] [Related]
10. DCVax®-L--developed by Northwest Biotherapeutics.
Polyzoidis S; Ashkan K
Hum Vaccin Immunother; 2014; 10(11):3139-45. PubMed ID: 25483653
[TBL] [Abstract][Full Text] [Related]
11. Immunological responses in a patient with glioblastoma multiforme treated with sequential courses of temozolomide and immunotherapy: case study.
Heimberger AB; Sun W; Hussain SF; Dey M; Crutcher L; Aldape K; Gilbert M; Hassenbusch SJ; Sawaya R; Schmittling B; Archer GE; Mitchell DA; Bigner DD; Sampson JH
Neuro Oncol; 2008 Feb; 10(1):98-103. PubMed ID: 18079360
[TBL] [Abstract][Full Text] [Related]
12. Targeting EGFRvIII for glioblastoma multiforme.
Yang J; Yan J; Liu B
Cancer Lett; 2017 Sep; 403():224-230. PubMed ID: 28649003
[TBL] [Abstract][Full Text] [Related]
13. Immune modulation associated with vascular endothelial growth factor (VEGF) blockade in patients with glioblastoma.
Thomas AA; Fisher JL; Hampton TH; Christensen BC; Tsongalis GJ; Rahme GJ; Whipple CA; Steel SE; Davis MC; Gaur AB; Lewis LD; Ernstoff MS; Fadul CE
Cancer Immunol Immunother; 2017 Mar; 66(3):379-389. PubMed ID: 27942839
[TBL] [Abstract][Full Text] [Related]
14. An Update on the Role of Immunotherapy and Vaccine Strategies for Primary Brain Tumors.
Neagu MR; Reardon DA
Curr Treat Options Oncol; 2015 Nov; 16(11):54. PubMed ID: 26454859
[TBL] [Abstract][Full Text] [Related]
15. A single-institution phase II trial of radiation, temozolomide, erlotinib, and bevacizumab for initial treatment of glioblastoma.
Clarke JL; Molinaro AM; Phillips JJ; Butowski NA; Chang SM; Perry A; Costello JF; DeSilva AA; Rabbitt JE; Prados MD
Neuro Oncol; 2014 Jul; 16(7):984-90. PubMed ID: 24637230
[TBL] [Abstract][Full Text] [Related]
16. Dendritic cell vaccination combined with temozolomide retreatment: results of a phase I trial in patients with recurrent glioblastoma multiforme.
Hunn MK; Bauer E; Wood CE; Gasser O; Dzhelali M; Ancelet LR; Mester B; Sharples KJ; Findlay MP; Hamilton DA; Hermans IF
J Neurooncol; 2015 Jan; 121(2):319-29. PubMed ID: 25366363
[TBL] [Abstract][Full Text] [Related]
17. Phase II trial of temozolomide (TMZ) plus irinotecan (CPT-11) in adults with newly diagnosed glioblastoma multiforme before radiotherapy.
Quinn JA; Jiang SX; Reardon DA; Desjardins A; Vredenburgh JJ; Friedman AH; Sampson JH; McLendon RE; Herndon JE; Friedman HS
J Neurooncol; 2009 Dec; 95(3):393-400. PubMed ID: 19533023
[TBL] [Abstract][Full Text] [Related]
18. Glioblastoma in the elderly: the effect of aggressive and modern therapies on survival.
Babu R; Komisarow JM; Agarwal VJ; Rahimpour S; Iyer A; Britt D; Karikari IO; Grossi PM; Thomas S; Friedman AH; Adamson C
J Neurosurg; 2016 Apr; 124(4):998-1007. PubMed ID: 26452121
[TBL] [Abstract][Full Text] [Related]
19. Chemoirradiation for glioblastoma multiforme: the national cancer institute experience.
Ho J; Ondos J; Ning H; Smith S; Kreisl T; Iwamoto F; Sul J; Kim L; McNeil K; Krauze A; Shankavaram U; Fine HA; Camphausen K
PLoS One; 2013; 8(8):e70745. PubMed ID: 23940635
[TBL] [Abstract][Full Text] [Related]
20. Predictors of Response to Autologous Dendritic Cell Therapy in Glioblastoma Multiforme.
Jan CI; Tsai WC; Harn HJ; Shyu WC; Liu MC; Lu HM; Chiu SC; Cho DY
Front Immunol; 2018; 9():727. PubMed ID: 29910795
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
